HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Products In Brief

This article was originally published in The Rose Sheet

Executive Summary

Transdel: La Jolla, Calif.-based pharmaceutical company developing non-invasive, topically administered medications says it may be able to generate revenue this year by expanding its development program to include cosmetics/cosmeceuticals. Products would feature the same patented Transdel transdermal delivery system used in the start-up's lead product - Ketotransdel, a topical cream-based non-steroidal anti-inflammatory drug - which currently is in Phase III trials for acute pain. Transdel says it has initiated discussions with potential sales and marketing partners for specific cosmetic products
Advertisement

Related Content

Transdel Targeting Cellulite In ’09 While Finishing Trials For Anti-Pain Drug
Transdel Targeting Cellulite In ’09 While Finishing Trials For Anti-Pain Drug
Marketing In Brief
Marketing In Brief
Advertisement
UsernamePublicRestriction

Register

RS015936

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel